This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Landsburg DJ , Koike A , Nasta SD , Svoboda J , Schuster SJ , Wasik MA , Caponetti GC
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas
Cancer Immunol Immunother. 2021 Mar;70(3) :869-874
PMID: 32857184 URL: https://www.ncbi.nlm.nih.gov/pubmed/32857184
AbstractGiven the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p = 0.02 and 32 vs. 5%, p = 0.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p = 0.01 and 34 vs. 81%, p = 0.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL.
Notes1432-0851 Landsburg, Daniel J Orcid: 0000-0002-5077-4181 Koike, Alexa Nasta, Sunita D Svoboda, Jakub Schuster, Stephen J Wasik, Mariusz A Caponetti, Gabriel C Journal Article Germany Cancer Immunol Immunother. 2020 Aug 28. doi: 10.1007/s00262-020-02708-3.